IL2 and psoriasis: Human Fc-conjugated IL-2 molecules lose in vivo exposure as early as after the first dose (Figure S6), potentially due to anti-drug antibody (ADA) response; thus, we opted to evaluate the impact of IL-2 with a single dose in a short-term psoriasis model induced by application of the imiquimod (IMQ) cream.